Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amylyx Pharmaceuticals Inc (AMLX)
NASDAQ:AMLX
RESEARCH TOOLSreports
Amylyx Pharmaceuticals Inc (AMLX) Stock Price & Analysis
416 Followers
AMLX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.85 - $31.21
Previous Close$1.98
Volume1.47M
Average Volume (3M)3.26M
Market Cap
$134.21M
Enterprise Value-$232.92M
Total Cash (Recent Filing)$371.36M
Total Debt (Recent Filing)$4.24M
Price to Earnings (P/E)2.8
Beta1.02
Next Earnings
May 09, 2024EPS Estimate
>-$0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.70
Shares Outstanding67,782,139
10 Day Avg. Volume2,437,964
30 Day Avg. Volume3,256,699
Standard Deviation0.36
R-Squared0.02
Alpha0.00659
Financial Highlights & Ratios
Price to Book (P/B)0.29
Price to Sales (P/S)0.35
Price to Cash Flow (P/CF)2.30
P/FCF Ratio2.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.61
Enterprise Value/Gross Profit-0.66
Enterprise Value/Ebitda-11.09
Forecast
1Y Price Target
$4.50Price Target Upside130.77% Upside
Rating ConsensusHold
Number of Analyst Covering8
Amylyx Pharmaceuticals Inc News
PremiumCompany Announcements
Amylyx Pharmaceuticals Enacts Major Restructuring and Refocuses Strategy
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsEarly trial results included partial reversal in C-peptide phenotype and improvements in visual acuity, which suggest a promising effect of the drug.
Market PotentialWolfram syndrome may have a higher prevalence than previously thought, indicating a larger potential market.
Regulatory MilestoneIncreased C-peptide in treated patients with reduction in HbA1C, allows the company to negotiate for a surrogate biomarker for Wolfram syndrome which might allow for a potential accelerated approval pathway.
Bears Say
Clinical Trial ConcernsGiven the trial is an open label study with limited number of patients and short follow-up, investor sentiment is unlikely to improve until phase 3 data.
Drug Approval UncertaintyNo drug is currently approved for Wolfram syndrome, and the regulatory path for AMX0035's approval is yet to be discussed with the FDA.
Market WithdrawalRelyvrio/Albrioza will be discontinued in both US and Canada and will no longer be available for patients.
---
Ownership Overview
46.22% Insiders
20.75% Mutual Funds
15.56% Other Institutional Investors
17.48% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AMLX FAQ
What was Amylyx Pharmaceuticals Inc’s price range in the past 12 months?
Amylyx Pharmaceuticals Inc lowest stock price was $1.85 and its highest was $31.21 in the past 12 months.
What is Amylyx Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Amylyx Pharmaceuticals Inc’s upcoming earnings report date?
Amylyx Pharmaceuticals Inc’s upcoming earnings report date is May 09, 2024 which is in 14 days.
How were Amylyx Pharmaceuticals Inc’s earnings last quarter?
Amylyx Pharmaceuticals Inc released its earnings results on Feb 22, 2024. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.228 by -$0.158.
Is Amylyx Pharmaceuticals Inc overvalued?
According to Wall Street analysts Amylyx Pharmaceuticals Inc’s price is currently Undervalued.
Does Amylyx Pharmaceuticals Inc pay dividends?
Amylyx Pharmaceuticals Inc does not currently pay dividends.
What is Amylyx Pharmaceuticals Inc’s EPS estimate?
Amylyx Pharmaceuticals Inc’s EPS estimate is >-$0.01.
How many shares outstanding does Amylyx Pharmaceuticals Inc have?
Amylyx Pharmaceuticals Inc has 67,782,140 shares outstanding.
What happened to Amylyx Pharmaceuticals Inc’s price movement after its last earnings report?
Amylyx Pharmaceuticals Inc reported an EPS of $0.07 in its last earnings report, missing expectations of $0.228. Following the earnings report the stock price went up 21.097%.
Which hedge fund is a major shareholder of Amylyx Pharmaceuticals Inc?
Among the largest hedge funds holding Amylyx Pharmaceuticals Inc’s share is Viking Global Investors LP. It holds Amylyx Pharmaceuticals Inc’s shares valued at 44M.
---
Amylyx Pharmaceuticals Inc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.50 (130.77% Upside)
$4.50 (130.77% Upside)
Blogger Sentiment
Bullish
AMLX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $270.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 8.7%
Last 30 Days ▼ 8.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-93.62%
12-Months-Change
Fundamentals
Return on Equity
12.73%
Trailing 12-Months
Asset Growth
32.19%
Trailing 12-Months
Company Description
Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases.
---
AMLX Earnings Call
Q4 2024
0:00 / 0:00
---
AMLX Stock 12 Months Forecast
Average Price Target
$4.50
▲(130.77% Upside)
Technical Analysis
Best Analysts Covering AMLX
1 Year
1 Year Success Rate
3/16 ratings generated profit
1 Year Average Return
-25.55%
reiterated a buy rating 14 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 18.75% of your transactions generating a profit, with an average return of -25.55% per trade.
---